A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma

This study is testing a new drug called OJP-001 in patients with adult T-cell leukemia/lymphoma (ATL) — a rare and aggressive blood cancer caused by the HTLV-1 virus — whose cancer has come back or not responded to previous treatment. **You may be eligible if...** - You are between 20 and 85 years old - You have a confirmed diagnosis of aggressive ATL (acute, lymphoma type, or chronic with unfavorable factors) - You are HTLV-1 antibody positive - Your cancer has relapsed after previous treatment including mogamulizumab, OR you cannot tolerate mogamulizumab, OR you relapsed after a stem cell transplant - You have cancer cells in your blood (peripheral blood lesion) - You are in reasonably good health (ECOG 0–2) with a life expectancy of more than 3 months **You may NOT be eligible if...** - You have indolent (slow-growing) ATL - Your organ function (liver, kidneys) is significantly impaired - Your expected survival is less than 3 months Talk to your doctor to see if this trial is right for you.